MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorSilva, Glenda Nicioli da
dc.creatorCamargo, Elaine Aparecida de
dc.creatorVentura Savio, Andre Luiz
dc.creatorSalvadori, Daisy Maria Favero
dc.date2014-12-03T13:10:36Z
dc.date2016-10-25T20:10:52Z
dc.date2014-12-03T13:10:36Z
dc.date2016-10-25T20:10:52Z
dc.date2014-07-01
dc.date.accessioned2017-04-06T06:21:07Z
dc.date.available2017-04-06T06:21:07Z
dc.identifierMolecular Biology Reports. Dordrecht: Springer, v. 41, n. 7, p. 4613-4621, 2014.
dc.identifier0301-4851
dc.identifierhttp://hdl.handle.net/11449/112299
dc.identifierhttp://acervodigital.unesp.br/handle/11449/112299
dc.identifier10.1007/s11033-014-3332-1
dc.identifierWOS:000338283000046
dc.identifierhttp://dx.doi.org/10.1007/s11033-014-3332-1
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/923064
dc.descriptionThe combination of gemcitabine and cisplatin has been shown previously to elicit a synergistic therapeutic effect on bladder cancer cell lines and result in reduced cell survival. However, the precise mechanism by which cells die has not been elucidated. Cell cycle-related genes are the predominant targets of chemotherapeutic protocols. Therefore, molecular biomarkers that are predictive of therapeutic outcomes associated with tumor sensitivity might be important for optimal treatment protocol selection. The aim of this study was to investigate the changes in gene expression in cell cycle-related genes that were induced by cisplatin, gemcitabine or a combined treatment using both agents in a low-grade urinary bladder transitional carcinoma cell line (RT4). The following three treatment protocols were used: 1.0 mu M cisplatin, 1.56 mu M gemcitabine and a combination of 1.0 mu M cisplatin and 1.56 mu M gemcitabine. Cytometry and morphology analysis (by phase-contrast photomicrography) were performed in addition to pathway-specific gene expression analysis using quantitative RT-PCR gene arrays. The following results were observed after 1.0 mu M cisplatin treatment: (1) a decrease in cell number, (2) an increased percentage of scattered cells and (3) downregulated expression of genes related to cell cycle arrest, G1/S-to-mitotic cell cycle transition, DNA repair, apoptosis, transcription and mitosis. Treatment with 1.56 mu M gemcitabine, or with both drugs simultaneously, induced the following effects: (1) a decrease in cell number, (2) an increased percentage of scattered and elongated cells, (3) the modulation of genes that are predominantly involved in DNA repair and (4) a significant upregulation of genes related to cell cycle arrest. Reduced cell density was observed after the combined treatment compared to the two other single-agent protocols. The downregulation of MRE11A and SKP2 was observed only in cells subjected to the combined treatment. In conclusion, cisplatin, gemcitabine and the combination of both drugs elicited distinct toxicogenomic effects in the RT4 bladder transitional carcinoma cell line, although disruptions in the expression of cell cycle control-related genes and other pathways responsible for cell survival were observed for all of the protocols. MRE11A and SKP2 downregulation appeared to be responsible for the synergistic therapeutic effects elicited by cisplatin and gemcitabine.
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.languageeng
dc.publisherSpringer
dc.relationMolecular Biology Reports
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCisplatin
dc.subjectGemcitabine
dc.subjectGene expression profiling
dc.subjectRT4 cell line
dc.titleMRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells
dc.typeOtro


Este ítem pertenece a la siguiente institución